The apolipoprotein B and apolipoprotein A-I Ratio serves as a strong prognostic factor for the overall survival of patients with colorectal cancer

Background The lipid metabolism status of patients with colorectal cancer (CRC) has not been understood comprehensively. The present study investigated the characteristics of lipid metabolism parameters in CRC patients with or without metastases and identified the independent prognostic factors of long-term prognosis. Methods The clinicopathological data of 231 CRC patients along with 259 formalin-fixed paraffin-embedded samples with or without liver or lung metastasis were retrieved and stained for apolipoprotein B (apoB) via immunohistochemistry (IHC) in our center. The correlation and multivariable analysis between blood circulating apolipoprotein A-I (apoA1), apoB and overall survival (OS) were analyzed. Results In the multivariable analysis, apoA1, apoB and apolipoprotein B and apolipoprotein A-I (apoB/A) ratio, were identified as independent prognostic factors for OS. Moreover, the apoB/A ratio showed a significantly negative association with OS time (R=-0.187, P=0.004). CRC patients with low apoB/A ratio had better 1-, 3- and 5-year OS rates than those who had high apoB/A ratio (87.1%, 54.3%, and 37.1% vs. 92.5%, 72.0%, and 59.5%, respectively, P=0.001). On histological level, similar expression intensity of apoB between primary CRC and liver metastases indicated better prognostic outcomes than those with different expression levels (100%, 83.3%, and 77.8% vs. 100%, 66.7%, and 33.3%, respectively; P=0.033). Higher level of apoB in the primary CRC interprets into increased incidence of liver metastases. However, the apoB expression levels in the CRC tumor were not parallel to the circulating lipid metabolism parameters. Conclusions The apoB/A ratio was a reliable independent prognostic factor for predicting the long-term OS of CRC patients. Moreover, the IHC of the primary CRC and metastatic lesions verified the metastatic potential of apoB through a different aspect. Lipid metabolism status for cancer progression reported in the present study possessed potentially prognostic value, but bench-scale studies are needed for their future clinical applications.

[1]  Jiong Cai,et al.  Incidence, mortality, survival, risk factor and screening of colorectal cancer: A comparison among China, Europe, and northern America. , 2021, Cancer letters.

[2]  I. Amit,et al.  NASH limits anti-tumour surveillance in immunotherapy-treated HCC , 2021, Nature.

[3]  A. Jemal,et al.  Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries , 2021, CA: a cancer journal for clinicians.

[4]  Zhongguo Zhou,et al.  Tescalcin is an unfavorable prognosis factor that regulats cell proliferation and survival in hepatocellular carcinoma patients , 2020, Cancer communications.

[5]  M. Christian,et al.  KRAS Status is Associated with Metabolic Parameters in Metastatic Colorectal Cancer According to Primary Tumour Location , 2020, Pathology & Oncology Research.

[6]  F. Shidfar,et al.  Impact of phytosterol supplementation on plasma lipoprotein(a) and free fatty acid (FFA) concentrations: A systematic review and meta-analysis of randomized controlled trials. , 2019, Nutrition, metabolism, and cardiovascular diseases : NMCD.

[7]  D. Ma,et al.  MicroRNA-217 inhibits proliferation and promotes apoptosis of small cell lung cancer cells via targeting PCDH8. , 2019, Panminerva medica.

[8]  Z. Wang,et al.  Identifying the key genes and microRNAs in colorectal cancer liver metastasis by bioinformatics analysis and in vitro experiments , 2018, Oncology reports.

[9]  Kyungjin Kim,et al.  A splice variant of human Bmal1 acts as a negative regulator of the molecular circadian clock , 2018, Experimental & Molecular Medicine.

[10]  Ju-Seog Lee,et al.  Clinical significance of APOB inactivation in hepatocellular carcinoma , 2018, Experimental & Molecular Medicine.

[11]  Robert C. Mines,et al.  Aldolase B-Mediated Fructose Metabolism Drives Metabolic Reprogramming of Colon Cancer Liver Metastasis. , 2018, Cell metabolism.

[12]  M. Hussain,et al.  Lipid transfer proteins in the assembly of apoB-containing lipoproteins , 2018, Journal of Lipid Research.

[13]  A. Jemal,et al.  Cancer statistics, 2018 , 2018, CA: a cancer journal for clinicians.

[14]  J. Engstrand,et al.  Colorectal cancer liver metastases – a population-based study on incidence, management and survival , 2018, BMC Cancer.

[15]  Z. Li,et al.  Aberrant Lipid Metabolism in Hepatocellular Carcinoma Revealed by Liver Lipidomics , 2017, International journal of molecular sciences.

[16]  T. Azuma,et al.  Differences in elongation of very long chain fatty acids and fatty acid metabolism between triple-negative and hormone receptor-positive breast cancer , 2017, BMC Cancer.

[17]  Steven J. M. Jones,et al.  Comprehensive and Integrative Genomic Characterization of Hepatocellular Carcinoma , 2017, Cell.

[18]  Yu Xia,et al.  Lipid Desaturation Is a Metabolic Marker and Therapeutic Target of Ovarian Cancer Stem Cells. , 2017, Cell stem cell.

[19]  J. Massagué,et al.  Metastatic colonization by circulating tumour cells , 2016, Nature.

[20]  W. Strum Colorectal Adenomas. , 2016, The New England journal of medicine.

[21]  C. Tournigand,et al.  Therapeutic strategy in unresectable metastatic colorectal cancer: an updated review , 2015, Therapeutic advances in medical oncology.

[22]  A. Barkun,et al.  Obesity and colorectal cancer , 2013, Gut.

[23]  G. Walldius The apoB/apoA-I Ratio is a Strong Predictor of Cardiovascular Risk , 2012 .

[24]  J. Gallacher,et al.  Lipid-related markers and cardiovascular disease prediction. , 2012, JAMA.

[25]  D. Hanahan,et al.  Hallmarks of Cancer: The Next Generation , 2011, Cell.

[26]  J. Hunt,et al.  KRAS gene mutation in colorectal cancer is correlated with increased proliferation and spontaneous apoptosis. , 2011, American journal of clinical pathology.

[27]  C. la Vecchia,et al.  Metabolic syndrome is associated with colorectal cancer in men. , 2010, European journal of cancer.

[28]  J. Shaw,et al.  The metabolic syndrome: prevalence in worldwide populations. , 2004, Endocrinology and metabolism clinics of North America.

[29]  F. A. Coller,et al.  THE PROGNOSTIC SIGNIFICANCE OF DIRECT EXTENSION OF CARCINOMA OF THE COLON AND RECTUM , 1954, Annals of surgery.

[30]  O. Warburg,et al.  THE METABOLISM OF TUMORS IN THE BODY , 1927, The Journal of general physiology.